Biologist Clemens Arvay elaborately explains the risks of genetic vaccines such as DNA- and RNA-vaccines. He warns of shortened admission procedures as they were recommended by Bill Gates and some experts. Beyond the specific risks are autoimmune diseases and an increased cancer risk. GERMAN VERSION: – Footnotes:
[1] NYU Langone Health, A US clinical trial for COVID-19 mRNA vaccine, in: Medical Express, 5th May 2020,
[2] McKee S., UK COVID-19 vaccine to begin human testing, in: Pharma Times, 22nd April 2020,
[3] Karberg S. and Vogt R., Erste klinische Studie in Deutschland zugelassen, in: Der Tagesspiegel, 22nd April 2020,
[4] Gates B., The first modern pandemic: the scientific advances we need to stop COVID-19, in: GatesNotes, 23rd April 2020,
[5] Gates B.: »There will be a trade-off, we will have less safety testing than we typically would have« (quote), in: BBC Breakfast, Interview with Bill Gates, 12th April 2020, time mark 7:40,
[6] Gillmann B., SARS-Impfstoffe: Virologe Drosten: »Wir müssen Regularien für Impfstoffe außer Kraft setzen«, in: Handelsblatt, 19th March 2020,
[7] World Health Organization (WHO), DRAFT landscape of COVID-19 candidate vaccines – 20 April 2020,
[8] Murphy K., Travers P., and Walport M. (2014), Janeway Immunologie, 7th edition, p. 880, Springer / Spektrum Publishing, Berlin / Heidelberg.
[9] Tobler K., Ackermann M., and Fraefel C. (2016), Allgemeine Virologie (General Virology), p. 263-265, UTB / Haupt Publishing, Bern.
[10] Verbeke R., Lentacker, I., De Smedt S., and Dewitte H. (2019), Three decades of messenger RNA vaccine development, in: Nano Today, Vol. 28,
[11] Medjitna T., Stadler C., Bruckner L., Griot C., and Ottinger H. (2006), DNA vaccines: safety aspect assessment and regulation, in: Developments of Biologicals, Vol. 126, p. 261-270, www.ncbi.nlm.nih.gov/pubmed/17058502
[12] Schalk J., Mooi F., Berbers G., van Aerts L., Ovelgönne H., and Kimman T. (2006), Preclinical and clinical safety studies on DNA vaccines, in: Human Vaccines, Vol. 2, Iss. 2, p. 45-53,
[13] Hobernik D. and Bros M. (2018), DNA vaccines: how far from clinical use?, in: International Journal of Molecular Sciences, Vol 9, Iss. 11, p. 3605, www.ncbi.nlm.nih.gov/pmc/articles/PMC6274812/
[14] (a) Hasson S., Al-Busaidi J., and Sallam T. (2015), The past, current, and future trends in DNA vaccine immunisations, in: Asian Pacific Journal of Tropical Biomedicine, Vol. 5, Iss. 5, p. 344-353, par. 5.2, and
(b) Ura T., Okuda K,. and Shimada M. (2014), Development in viral vector based vaccines, in: Vaccines, Vol. 2, Iss. 3, p. 624-641, par. 3.4,
[15] Lurie N., Saville M., Hatchett R., and Halton J. (2020), Perspective: Developing COVID-19 vaccines at pandemic speed, in: The New England Journal of Medicine,
(PDF page 2, middle column)
[16] Jiang S. (2020), Don´t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees, in: Nature, 16th March 2020,
[17] Takano T., Yamada S., Doki T., and Hohdatsu T. (2019), Pathogenesis of oral type one feline infectious peritonitis virus (FIPV) infection: antibody-dependent enhancement infection of cats with type I FIPV via the oral route, in: Journal of Veterinary Medical Science, Vol. 81, Iss. 6, p. 799-948,
[18] Pinkstone J., A “wolf in sheep’s clothing”: Scientists unravel the disguise that lets the coronavirus hide from the human immune system, in: Daily Mail, 8th April 2020,
